Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbe1d40faa1ed62003e4b49d8b278688 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-587 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-29 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-232 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-201 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C57-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-587 |
filingDate |
2004-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0bfe9d4f49aa8866bc6c8f6af7458c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14cf1ba48bf01ee7799226505565a2fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94cc0387c82f5739d34e8eee08916215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c2216d20d638790ba450a4715a3993a |
publicationDate |
2008-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2008194684-A1 |
titleOfInvention |
Treatment of Neurodegenerative Conditions |
abstract |
A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β levels in the patient to therapeutic levels. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009023807-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107595889-A |
priorityDate |
2003-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |